Results 191 to 196 of about 13,139 (196)

Systemic tetrahydrobiopterin (BH4) levels and coronary artery disease.

Cardiology, 2000
Walter R, Blau N, Kierat L, Schoedon G, Reinhart W H   +4 more
openaire   +2 more sources

Sapropterin Is Safe and Effective in Patients less than 4-Years-Old with BH4-Responsive Phenylalanine Hydroxylase Deficiency

Journal of Pediatrics, 2014
Haruo Shintaku, Toshihiro Ohura
exaly  

The treatment of phenylalanine hydroxylase (PAH)-deficient BH4-responsive patints with tetrahydrobiopterin (BH4): tolerance to Phe and response to BH4.

2005
LEUZZI, Vincenzo, CARDUCCI, Claudia, DE LEO S, MONTIERI P, CARDUCCI, Carla, ANTONOZZI I.   +5 more
openaire   +2 more sources

Tetrahydrobiopterin (BH4) treatment stabilizes tyrosine hydroxylase: Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock-in mouse model

Journal of Inherited Metabolic Disease
Alba Tristán-Noguero, Kunwar Jung K C, Aurora Martinez   +2 more
exaly  

Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4.

2007
CRISTIAN DUMITRESCU, BIONDI, Roberto, YONG XIA, ARTURO J. CARDOUNEL, LAWRENCE J. DRUHAN, R. BIONDI   +5 more
openaire   +1 more source

The effects of tetrahydrobiopterin (BH4) treatment on cerebral metabolism in phenylketonuric mice

2015
PASCUCCI, Tiziana, Fiori, Elena, CARDUCCI, Claudia, LEUZZI, Vincenzo, PUGLISI ALLEGRA, Stefano   +4 more
openaire   +1 more source